Dr. Euy Sung Moon | FB 09 - Department of Chemistry


	Johannes Gutenberg-University Mainz Department of Chemistry Duesbergweg 10–14 Room 2221.01.133 55128 Mainz Phone: +49 6131/39-36200 E-mail: emoon01@uni-mainz.de
.	.
2011–2015	Bachelor Studies in Chemistry at JGU Mainz
2014	Bachelor Thesis in the group of Prof. S. R. Waldvogel at JGU Mainz
2016–2018	Master Studies in the Chemistry at JGU Mainz
2016–2017	Research Stay in the group of Dr. J. Brgoch at Univ. of Houston, USA
2018	Master Thesis in the group of Prof. Dr. F. Rösch at JGU Mainz
2018–2021	PhD Studies in the group of Prof. Dr. F. Rösch Subject: Radiopharmaceutical Chemistry
Since 2022	PostDoc in the group of Prof. Dr. S. R. Waldvogel Project management, ETOS project
.	.
.	.
Publications:	S. Ballal, M. P. Yadav, E. S. Moon, F. Roesch, S. Kumari, S. Agarwal, M. Tripathi, R. K. Sahoo, B. S. Mangu, A. Tupalli, C. Bal, Novel Fibroblast Activation Protein Inhibitor-Based targeted Theranostics for Radioiodine Refractory differentiated Thyroid Cancer Patients: A Pilot Study, Thyroid 2022, 32, 65–77. [DOI: 10.1089/thy.2021.0412] S. Ballal, M. P. Yadav, E. S. Moon, V. Kramer, F. Roesch, S. Kumari, C. Bal, First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [¹⁷⁷Lu]Lu-DOTA.SA.FAPi and [¹⁷⁷Lu]Lu-DOTAGA.(SA.FAPi)₂, Pharmaceuticals 2021, 14, 1212. [DOI: 10.3390/ph14121212] E. S. Moon, S. Ballal, M. P. Yadav, C. Bal, Y. Van Rymenant, S. Stephan, A. Bracke, P. Van der Veken, I. De Meester, F. Roesch, Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: A step to improve tumor uptake and retention time, AJNMMI 2021, 11(6), 476–491. S. Imlimthan, E. S. Moon, H. Rathke, A. Afshar-oromieh, F. Rösch, A. Rominger, E. Gourni, New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors : A Rational Review and Current Progress, Pharmaceuticals 2021, 14, 1023. [DOI: 10.3390/ph14101023] B. Kreppel, M. A. Gonzalez-carmona, G. Feldmann, J. Küppers, E. S. Moon, M. Marinova, F. C. Gaertner, Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours, Nuklearmedizin 2021, 60, 344–354. [DOI: 10.1055/a-1521-8604] T. Grus, H. Lahnif, B. Klasen, E. S. Moon, L. Greifenstein, F. Roesch, Squaric Acid-Based Radiopharmaceuticals for Tumor Imaging and Therapy, Bioconjug. Chem. 2021, 32, 1223–1231. [DOI: 10.1021/acs.bioconjchem.1c00305] E. S. Moon, Y. Van Rymenant, S. Battan, J. De Loose, A. Bracke, P. Van der Veken, I. De Meester, F. Roesch, In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi, Molecules 2021, 26, 3482. [DOI: 10.3390/molecules26123482] B. Klasen, E. S. Moon, F. Rösch, AAZTA⁵-squaramide ester competing with DOTA-, DTPA- and CHX-A''-DTPA-analogues: Promising tool for ¹⁷⁷Lu-labeling of monoclonal antibodies under mild conditions, Nucl. Med. Biol. 2021, 96–97, 80–93. [DOI: 10.1016/j.nucmedbio.2021.03.007] F. Rosar, H. Bohnenberger, E. S. Moon, F. Rösch, A. Denig, D. Vincenz-Zörner, M. A. Hoffmann, F. Khreish, S. Ezziddin, M. Schreckenberger, H. G. Buchholz, A. Schaefer-Schuler, Impact of prompt gamma emission of ⁴⁴Sc on quantification in preclinical and clinical PET systems, Appl. Radiat. Isot. 2021, 170, 1–8. [DOI: 10.1016/j.apradiso.2021.109599] M. Hofstetter, E. S. Moon, F. D’Angelo, L. Geissbühler, I. Alberts, A. Afshar-Oromieh, F. Rösch, A. Rominger, E. Gourni, Effect of the versatile bifunctional chelator AAZTA⁵ on the radiometal labelling properties and the in vitro performance of a gastrin releasing peptide receptor antagonist, EJNMMI Radiopharm. Chem. 2020, 5, 29. [DOI: 10.1186/s41181-020-00115-8] J. P. Sinnes, U. Bauder-Wüst, M. Schäfer, E. S. Moon, K. Kopka, F. Rösch, ⁶⁸Ga, ⁴⁴Sc and ¹⁷⁷Lu-labeled AAZTA⁵-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues, EJNMMI Radiopharm. Chem. 2020, 5, 28. [DOI: 10.1186/s41181-020-00107-8] S. Ballal, M. P. Yadav, E. S. Moon, V. Kramer, F. Roesch, S. Kumari, M. Tripathi, S. T. ArunRaj, S. Sarswat, C. Bal, Biodistribution, pharmacokinetics, dosimetry of [⁶⁸Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [¹⁸F]F-FDG PET/CT in patients with various cancers, Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 1915–1931. [DOI: 10.1007/s00259-020-05132-y] S. Ballal, M. P. Yadav, V. Kramer, E. S. Moon, F. Roesch, M. Tripathi, S. Mallick, S. T. ArunRaj, C. Bal, A theranostic approach of [⁶⁸Ga]Ga-DOTA.SA.FAPi PET/CT-guided [¹⁷⁷Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy, Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 942–944. [DOI: 10.1007/s00259-020-04990-w] E. S. Moon, F. Elvas, V. Gwendolyn, S. De Lombaerde, C. Vangestel, S. De Bruycker, A. Bracke, E. Eppard, L. Greifenstein, B. Klasen, V. Kramer, S. Staelens, I. De Meester, P. Van der Veken, F. Rösch, Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA^5m chelators, EJNMMI Radiopharm. Chem. 2020, 5, 19. [DOI: 10.1186/s41181-020-00102-z] B. Kreppel, F. Gärtner, M. Marinova, U. Attenberger, M. Meisenheimer, M. Toma, G. Kristiansen, G. Feldmann, E. S. Moon, F. Roesch, P. Van der Veken, M. Essler, [⁶⁸Ga]Ga-DATA^5m.SA.FAPi PET/CT: Specific Tracer-uptake in Focal Nodular Hyperplasia and potential Role in Liver Tumor Imaging, Nuklearmedizin 2020, 59, 387–389. [DOI: 10.1055/a-1164-5667]